首页>投融资
Becton Dickinson
收并购
Becton, Dickinson and Co is a medical technology company with a particular emphasis on diagnostics and disposables.In July 2022, Becton, Dickinson and Co acquired MedKeeper.In April 2022, Becton, Dickinson and Co had completed its spinoff of Embecta Corp.In February 2022, Becton, Dickinson and Co had announced the sale of Cytognos by Vitro SA. Later that month, the company acquired Cytognos Sl completely.In December 2021, the company had acquired Tissuemed Ltd. Later that month, the company announced it completed the acquisition of Scanwell Health Inc.In November 2020, BD had acquired the medical business assets of CUBEX.In September 2018, Thermo Fisher Scientific had entered into a definitive agreement to acquire advanced bioprocessing business of BD Technologies.In July 2005, Becton Dickinson had agreed to sell its Clontech Laboratories Inc unit to Takara Bio for $60 million, The plan to sell Clontech had a
基本信息
-
公司全称Becton Dickinson and Co
-
类型医疗设备研发生产商、销售商
-
产业领域医疗器械
-
公司人数500人以上
-
地址One Becton Drive FRANKLIN LAKES NEW JERSEY 07417-1880; US; Telephone: +12018476800;
-
联系电话(201)847-6800
-
邮箱
-
成立时间1897-01-01
投融资
-
2024-12-02收并购未透露未透露
-
2023-08-02收并购未透露STERIS
-
2023-08-02收并购未透露STERISLazard
-
2020-07-31上市后再融资2400万美元United States Department of Defense
-
2016-03-08E~PreIPO未透露Apax Partners
-
2016-03-08上市后再融资未透露Apax Partners
-
2015-01-06上市未透露未透露
-
2015-01-06上市未透露未透露
-
1963-09-25上市未透露未透露
- 加载更多
相关投融资企业
C轮
Francis Medical is a dynamic medical device company committed to developing urological cancer treatments that are tough on cancer yet gentle on patients.In September 2020, Coloplast announced that it has completed a USD 4m (DKK 25m) equity investment in Francis Medical
收并购
Gynesonics is a developer of transcervical, uterus-preserving, incision-free technologies for diagnostic and therapeutic applications (avoiding invasive surgical techniques of hysterectomy or myomectomy for symptomatic uterine fibroids). Products include the Sonata system which combines intrauterine ultrasound guidance with targeted radiofrequency ablation.In April 2023, the company closed a financing round of $25M
未公开
PBS Biotech 是一次性生物反应器系统的领先制造商。PBS 生物反应器利用专有的“Vertical-Wheel TM ”技术来支持剪切敏感的细胞治疗产品。PBS Biotech愿景是成为世界上同种异体细胞疗法的标准制造平台。